Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 17/20 | 0.55 |
| ▸ | KCNJ11 | Q14654 | 17/20 | 0.55 |
| ▸ | ABCC8 | Q09428 | 16/20 | 0.55 |
| ▸ | KCNJ8 | Q15842 | 16/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6314271 | 0.80 | TP53 (0.47) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL6312587 | 0.80 | MAPK1 (0.51) | MEN1KMT2AALDH1A1ALOX15MAPK1 | |
| SCHEMBL6312851 | 0.76 | ALDH1A1 (0.46) | ABCC9KCNJ11ABCC8KCNJ8MEN1 | |
| SCHEMBL10113484 | 0.76 | GAA (0.62) | ABCC9KCNJ11ABCC8KCNJ8KMT2A | |
| SCHEMBL6321503 | 0.76 | USP2 (0.57) | ALDH1A1 | |
| SCHEMBL7098825 | 0.75 | ABCC9 (0.66) | ABCC9KCNJ11ABCC8KCNJ8ALDH1A1 | |
| SCHEMBL7104751 | 0.74 | ABCC9 (0.57) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL6315181 | 0.74 | MEN1 (0.49) | MEN1KMT2AALDH1A1ALOX15 | |
| SCHEMBL10113470 | 0.73 | GAA (0.71) | MEN1KMT2AALDH1A1 | |
| SCHEMBL6314041 | 0.73 | GUSB (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900214-B2 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1373223-A4 | CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1373223-A1 | CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002079169-A1 | CYANO-SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020143026-A1 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143026-A1 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | CCNB1, BUB1B, BUB1 | ABCC9 1305/4885KCNJ11 2455/4885ABCC8 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.